Safety and Immunogenicity of a Klebsiella Pneumoniae Tetravalent Bioconjugate Vaccine (Kleb4V)

  • End date
    Jun 20, 2022
  • participants needed
  • sponsor
    LimmaTech Biologics AG
Updated on 20 July 2021


In this study, the tetravalent bioconjugate candidate vaccine Kleb4V will be tested to obtain first-time-in-human (FTIH) data on its safety and immunogenicity in healthy adults.


Kleb4V is a tetravalent bioconjugate vaccine including O antigen-polysaccharides of the most predominant Klebsiella pneumoniae serotypes, which will be formulated with or without Adjuvant System, AS03. Study participants will be randomized towards Kleb4V Low dose with or without AS03, Kleb4V Target dose with or without AS03, or placebo.

The study will be conducted in two steps. In Step1 (safety cohort): safety and tolerability of Kleb4V without and with Adjuvant AS03 will be evaluated first in adults of 18-40 y, and subsequently in the target population of older adults 55-70 y. Enrolment will be staggered in groups of small numbers to the different doses and formulations.

In Step 2 (target cohort): Older adults (55-70y) will be concomitantly randomized to receive 1 of the 4 different vaccine formulations or placebo.

Condition Klebsiella Pneumoniae Infection
Treatment Placebo, Kleb4V target dose, Kleb4V target dose + AS03, Kleb4V low dose, Kleb4V low dose + AS03
Clinical Study IdentifierNCT04959344
SponsorLimmaTech Biologics AG
Last Modified on20 July 2021


Yes No Not Sure

Inclusion Criteria

Good general health by medical history, laboratory findings and physical examination before receiving vaccination as judged by the investigator (subjects with a minor controlled illness, such as mild controlled hypertension, asthma or COPD (Chronic Obstructive Pulmonary Disease), and without fever may be enrolled at the discretion of the investigator)
Subject who is willing and able to comply with the requirements of the protocol (e.g. completion of the diary cards, return for follow-up visits)
Signed written informed consent obtained from the subject
For Step 1 Groups 1 and 2 only: Female or male between 18-40 years (inclusive) of age
For Step 1 Groups 3 to 6, and Step 2: Female or male subjects between 55-70 (inclusive) years of age at the time of first vaccination
Female subjects of childbearing potential are eligible, as long as they practice adequate contraceptive measures from 2 months before the first vaccination until 1 month after the last vaccination

Exclusion Criteria

Health condition that, in the opinion of the investigator, may interfere with optimal participation in the study or place the volunteer at increased risk of adverse events (AEs) Study clinicians, in consultation with the principal investigator, will use clinical judgement on a case-by-case basis to assess safety risks under this criterion
Any clinically significant deviation from the normal range in biochemistry or hematology blood tests in the opinion of the investigator
Clinically significant abnormalities on physical examination
Suspected or known hypersensitivity (including allergy) to any of the vaccine components or to medicinal products or medical equipment whose use is foreseen in this study
History of allergy to any vaccine
Clinical conditions representing a contraindication to intramuscular vaccination and blood draws (e.g. coagulation disorder)
Acute or chronic, clinically significant cardiovascular, pulmonary, hepatic or renal abnormality diseases and/or insufficiency as determined by physical examination or laboratory tests. In particular: unstable current or history of coronary artery disease or cardiac insufficiency, uncontrolled hypertension, clinically significant history of myocardial infarction, atrial fibrillation, uncontrolled or clinically significant type 2 diabetes, current or history of rheumatoid arthritis or temporal arteritis, current acute or chronic active pulmonary diseases
Note: Subjects may be on chronic or as needed medications if, in the opinion
of the site principal investigator or appropriate sub-investigator, they pose
no additional risk to subject safety or assessment of reactogenicity and
immunogenicity and do not indicate a worsening of medical diagnosis or
\. Known or suspected impairment of immunological function, documented Human
Immunodeficiency Virus (HIV) infection, asplenia/splenectomy, or history of
autoimmune disease or lymphoproliferative disorder
\. Positive blood test for HBsAg, HCV (Hepatitis C Virus), HIV-1/2
\. Positive test for SARS-CoV-2 (severe acute respiratory syndrome
coronavirus type 2)
\. History of systemic administration of immunosuppressive drugs, i.e
corticosteroids, (PO/IV/IM) within the last 4 weeks prior to 1st vaccination
or for more than 14 consecutive days within 3 months prior to 1st vaccination
until the last blood sampling visit (i.e. prednisone or equivalent 20 mg/day)
Inhaled and topical steroids are allowed
\. Administration of anti-neoplastic and immune-modulating agents or
chemotherapy within 90 days prior to informed consent
\. Planned administration of a vaccine not foreseen by the study protocol
within 4 weeks prior to 1st vaccination and 4 weeks after last vaccination
Vaccination against seasonal influenza virus (or CoVID (Coronavirus disease)
vaccine if on the market) is allowed outside of +/- 7 days from each
\. Concurrently participating in another clinical study, at any time during
the study period, in which the subject has been or will be exposed to an
investigational or a non-investigational interventional vaccine/product
(pharmaceutical product)
\. Body Mass Index (BMI) <19 and >30
\. History of any chronic or progressive disease that according to judgement
of the investigator could interfere with the study outcomes or pose a threat
to the participant's health
\. Received an investigational or non-registered product (medicinal drug or
vaccine), other than the study vaccine within 3 months prior to 1st
administration of study vaccine, or planned use during the study period
\. Administration of immunoglobulin and/or any blood products within the
three months preceding the first dose of study vaccine
\. Blood donation of at least 500 mL blood draw within 3 months preceding
injection or planned during the study period as reported by subject
\. Use of any antibiotic therapy within 1 week preceding each injection
\. Subjects with an elective surgical intervention, planned during the study
period until 30 days after 2nd vaccination
\. Females lactating, or pregnancy or intention to become pregnant as
reported by subject
\. Current and/or history of chronic alcohol consumption and/or drug abuse
\. History of immune-mediated disease (see Table of pIMDs (potential Immune
Mediated Diseases) in Annex)
\. Heavy smokers (> 20 cigarettes per day)
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Preferred Language
Other Language
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note